title: Cerebral toxoplasmosis after rituximab therapy.
authors.forename: Gilles
authors.initials: G
authors.lastname: Safa
authors.forename: Laure
authors.initials: L
authors.lastname: Darrieux
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007074:Immunoglobulin G / Q000097:blood; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects*; D008279:Magnetic Resonance Imaging; D009336:Necrosis; D016133:Polymerase Chain Reaction; D000069283:Rituximab; D012871:Skin Diseases / Q000175:diagnosis / Q000188:drug therapy*; D014122:Toxoplasma / Q000235:genetics / Q000302:isolation & purification*; D016781:Toxoplasmosis, Cerebral / Q000175:diagnosis* / Q000209:etiology / Q000276:immunology; D014657:Vasculitis / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D015415:Biomarkers; D007074:Immunoglobulin G; D007155:Immunologic Factors; D000069283:Rituximab